Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Mental Health Research topic
No spam. Unsubscribe anytime.
House advances bill aligning Arizona law with rescheduling of psilocybin for clinical trials
Summary
Legislators advanced SB 15‑55, which would align Arizona law with federal rescheduling decisions to allow access to synthesized psilocybin in clinical trials; sponsors framed it as patient‑safety and research policy while noting current federal classification as Schedule I.
The House Committee of the Whole recommended Senate Bill 15‑55 as amended, a measure to align Arizona law to permit access to synthesized psilocybin being studied in clinical trials.
Representative Bliss, speaking for the Health and Human Services committee, said synthesized versions of psilocybin are under clinical study for mental health conditions and that Arizona does not automatically follow DEA rescheduling decisions. "That's the purpose of this bill, to align with their decision and allow patients to have access to new treatments," Bliss said.
Committee discussion framed the bill as enabling research and potential treatments for conditions such as PTSD, with the sponsor noting veterans’ groups had brought the issue forward. The transcript records that committee amendments were adopted and that the committee recommended the bill do pass as amended.
The committee’s recommendation was reported to the House and the bill was advanced to engrossing; committee and floor motions and amendments are recorded in the public minutes.
Ending: SB 15‑55 advances as amended for further House consideration; additional committee reports or floor votes will be recorded in subsequent session records.
